Decreases the number of senescent cells
Center for Molecular Cardiology, University of Zurich
In order to demonstrate the superiority of our formulation compared to other NAD+-based products, we compared onset of senescence in two different human cell types: endothelial cells (crucial to deliver blood nutrients to the skin) and keratinocytes (the most abundant cell type in the skin).
During ageing, the accumulation of senescent cells is observed. These cells are charatcerised by cell-cycle arrest, meaning cells stops replicating. Further, senescent cells secrete a number of proteins. This process is called senscence associated secretory phenotype or SASP. Structural changes in the nucleus, which form in response to DNA damage, manifest as disrupted nuclear lamina, DNA scars (DNA segments with chromatin alterations reinforcing senescence), and senescent associated heterochromatin foci (SAHF).
Our research, led by Professor Giovanni Camici, PhD Director of the Center for Molecular Cardiology at the University of Zurich and colleagues, showed that treatment with our liposomal formulation significantly reduces the number of senescent cells in both endothelial cells and keratinocytes compared to NAD+ alone.